TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more
TuHURA Biosciences Inc (HURA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.661x
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has a cash flow conversion efficiency ratio of -0.661x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.09 Million) by net assets ($16.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TuHURA Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how TuHURA Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TuHURA Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TuHURA Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
-0.021x |
|
UHT Unitech Co., Ltd.
TWO:6618
|
-0.091x |
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
0.123x |
|
PLIANT THERA.INC.DL-0001
F:9PT
|
N/A |
|
Nekkar Asa
OL:NKR
|
0.120x |
|
Kestrel Group, Ltd.
NYSE:KG
|
-0.023x |
|
OXFORD METRICS LS-0025
F:RNI
|
N/A |
|
Pacific Petroleum Transportation JSC
VN:PVP
|
N/A |
Annual Cash Flow Conversion Efficiency for TuHURA Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of TuHURA Biosciences Inc from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $14.59 Million | $-14.73 Million | -1.009x | -121.92% |
| 2024-06-30 | $-1.56 Million | $-7.18 Million | 4.604x | +854.42% |
| 2023-06-30 | $12.30 Million | $-7.51 Million | -0.610x | -106.95% |
| 2022-06-30 | $-747.82K | $-6.56 Million | 8.777x | +592.39% |
| 2021-06-30 | $10.58 Million | $-18.86 Million | -1.782x | +94.09% |
| 2020-06-30 | $263.00K | $-7.93 Million | -30.144x | -837.35% |
| 2019-06-30 | $1.97 Million | $-6.33 Million | -3.216x | -77.44% |
| 2018-06-30 | $5.44 Million | $-9.85 Million | -1.812x | -48.68% |
| 2017-06-30 | $6.58 Million | $-8.02 Million | -1.219x | -15.10% |
| 2016-06-30 | $4.86 Million | $-5.15 Million | -1.059x | -122.58% |
| 2015-06-30 | $-821.49K | $-3.85 Million | 4.690x | -- |